Gene expression inhibitor
The use of sardine seed oil extracted via supercritical or subcritical carbon dioxide methods addresses the need for effective gene expression suppressors of 5-LOX and COX2, achieving a potent anti-inflammatory effect by inhibiting leukotriene and prostaglandin production.
Patent Information
- Application Number
- JP2023080868
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-16
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2043-05-16
AI Technical Summary
Existing technologies lack effective gene expression suppressors for the 5-LOX and COX2 genes, which are involved in the synthesis of leukotrienes and prostaglandins, respectively, leading to excessive inflammatory reactions.
A gene expression inhibitor containing sardine seed oil, extracted using supercritical or subcritical carbon dioxide methods, suppresses the expression of the 5-LOX and COX2 genes, thereby reducing the production of leukotrienes and prostaglandins.
The inhibitor effectively suppresses the expression of both genes, providing a powerful anti-inflammatory effect by reducing the synthesis of leukotrienes and prostaglandins, which are known to cause inflammation.
Smart Images

Figure 2024165048000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a gene expression inhibitor that inhibits the expression of the 5-LOX gene and / or the COX2 gene. [Background technology]
[0002] Inflammation, one of the body's defense reactions, is controlled by various chemicals. When inflammation occurs, arachidonic acid, which is bound to phospholipids in cell membranes, produces physiologically active substances called leukotrienes and prostaglandins through the action of enzymes, which cause inflammatory reactions such as pain and fever.
[0003] The 5-LOX (5-lipoxygenase) gene is a gene involved in the synthesis of leukotrienes induced by inflammation. The COX2 (cyclooxygenase 2) gene is a gene involved in the synthesis of prostaglandins induced by inflammation. While the inflammatory response is essential for biological defense, an excessive inflammatory response can be harmful to the body. Substances that suppress the expression of these genes are being researched to suppress excessive inflammatory responses. For example, Patent Document 1 is known as a substance related to the suppression of COX2 gene expression. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] WO01 / 030341 Summary of the Invention [Problem to be solved by the invention]
[0005] An object of the present invention is to provide a novel gene expression-inhibiting agent which inhibits the expression of the 5-LOX gene and / or COX2 gene. [Means for solving the problem]
[0006] The present inventors have conducted extensive research to solve the above problems, and as a result have found that the following invention meets the above object, thereby completing the present invention. <1> A gene expression inhibitor that contains sea buckthorn seed oil as an active ingredient and suppresses the expression of the 5-LOX gene. <2> Inhibits the expression of the COX2 gene. <1> A gene expression inhibitor according to claim 1. <3> A gene expression inhibitor that contains sea buckthorn seed oil as an active ingredient and suppresses the expression of the COX2 gene. <4> The seabuckthorn seed oil is a supercritical carbon dioxide extract and / or a subcritical carbon dioxide extract of seabuckthorn seeds. <1> from <3> 2. A gene expression inhibitor according to any one of claims 1 to 11. Effect of the Invention
[0007] According to the present invention, there is provided a novel gene expression-suppressing agent which suppresses the expression of the 5-LOX gene and / or the COX2 gene. [Brief description of the drawings]
[0008] [Figure 1] FIG. 1 shows the results of a test evaluating the expression of the 5-LOX gene and the COX2 gene. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] The following is a detailed description of the embodiments of the present invention, but the following description of the constituent elements is one example (representative example) of the embodiment of the present invention, and the present invention is not limited to the following content as long as the gist of the present invention is not changed. Note that in this specification, when the expression "~" is used, it is used as an expression including the numerical value or physical property value before and after it.
[0010] <Gene expression inhibitors> The present invention relates to a gene expression inhibitor that contains seabuckthorn seed oil as an active ingredient and suppresses the expression of the 5-LOX gene. The present invention also relates to a gene expression inhibitor that contains seabuckthorn seed oil as an active ingredient and suppresses the expression of the COX2 gene. That is, the gene expression inhibitor of the present invention can suppress the expression of the 5-LOX gene and / or the COX2 gene.
[0011] (Sea Buckthorn Seed Oil) Sea buckthorn seed oil is an oil (hydrophobic component) extracted from sea buckthorn seeds. Sea buckthorn (Hippophae rhamnoides L.) is a plant of the Hippophae genus of the Elaeaceae family native to Eurasia. Sea buckthorn seeds can be extracted from the fruit itself or from the residue after processing the fruit. For example, the seeds can be selected from the residue removed when sea buckthorn fruits are pressed or strained to process them into juice such as liquid or puree, and used to extract oil. The seeds selected from the residue can be washed with water and dried as appropriate before being used to extract oil.
[0012] The method for extracting the oil is not particularly limited, and known methods can be used. Seabuckthorn seeds are crushed or pulverized as appropriate, and then extracted using an extraction method such as supercritical carbon dioxide extraction, subcritical carbon dioxide extraction, steam distillation, organic solvent extraction, or compression extraction, and the resulting extract can be used as seabuckthorn seed oil.
[0013] Among them, it is preferable to use supercritical carbon dioxide extraction method or subcritical carbon dioxide extraction method, which can extract at low temperature and extract heat-sensitive components without destroying them, and the sea buckthorn seed oil is preferably a supercritical carbon dioxide extract and / or subcritical carbon dioxide extract of sea buckthorn seeds. Specifically, the sea buckthorn seed oil is preferably obtained by a method having a step of using carbon dioxide in a supercritical state or subcritical state as an extraction solvent, extracting oil from sea buckthorn seeds, and removing carbon dioxide. The extraction conditions may be any temperature and pressure that carbon dioxide is in a supercritical state or subcritical state, for example, a temperature of 20 to 80°C and a pressure of 10 to 60 MPa, a temperature of 30 to 80°C and a pressure of 10 to 50 MPa, a temperature of 31 to 60°C and a pressure of 15 to 40 MPa, or a temperature of 31 to 40°C and a pressure of 20 to 30 MPa.
[0014] (Suppression of 5-LOX gene expression) The gene expression inhibitor of the present invention can suppress the expression of the 5-LOX gene, and can be used as a 5-LOX gene expression inhibitor. 5-LOX is also called 5-lipoxygenase, arachidonic acid 5-lipoxygenase, ALOX5, etc., and is an enzyme involved in the synthesis of leukotrienes. When cells are damaged by stimulation, arachidonic acid is released from cell membrane phospholipids. When 5-LOX acts on arachidonic acid, leukotrienes are produced. Leukotrienes are known to be involved in inflammation, and are known to act on the migration and activation of inflammatory cells, contract airway smooth muscle, and dilate blood vessels. The 5-LOX gene is a gene that codes for 5-LOX, and its official symbol listed in NCBI (http: / / www.ncbi.nlm.nih.gov / ) is ALOX5. The gene expression inhibitor of the present invention can reduce the transcription product and 5-LOX by suppressing or inhibiting the transcription from the 5-LOX gene to mRNA and the translation from mRNA to the 5-LOX encoded by the gene.
[0015] (Suppression of COX2 gene expression) The gene expression inhibitor of the present invention can suppress the expression of the COX2 gene, and can be used as a COX2 gene expression inhibitor. COX2 is also called cyclooxygenase 2, prostaglandin endoperoxide synthase 2, COX-2, or PTGS2, and is an enzyme involved in the synthesis of prostaglandins. When COX2 acts on arachidonic acid, prostaglandins are produced. Prostaglandins are known to have a fever effect, an inflammation-promoting effect, and an effect of enhancing pain. The COX2 gene is a gene that codes for COX2, and its official symbol listed in NCBI (http: / / www.ncbi.nlm.nih.gov / ) is PTGS2. The gene expression inhibitor of the present invention can suppress or inhibit the transcription of the COX2 gene to mRNA and the translation of the mRNA to the COX2 encoded by the gene, thereby reducing the transcript and COX2.
[0016] The gene expression inhibitor of the present invention can be used to suppress the expression of the 5-LOX gene and the COX2 gene. Both leukotrienes and prostaglandins are substances that cause inflammation. By suppressing the expression of both the 5-LOX gene and the COX2 gene, the production of leukotrienes and prostaglandins can be suppressed, and a stronger anti-inflammatory effect can be expected, which is preferable.
[0017] The gene expression inhibitor of the present invention can be used in various forms, such as liquids such as aqueous solutions, emulsions, dispersions, and emulsions; semi-solid forms such as gels, ointments, pastes, and creams; and solid forms. For example, it can be in the form of any external preparation, such as lotion, cosmetic solution, cream, milky lotion, sunscreen, cleanser, pack, cosmetic oil, body rinse, massage agent, scalp agent, hair wash, hair rinse, and lip care cosmetics. In the case of external preparations, a general amount for each external preparation can be used once to several times a day.
[0018] The gene expression inhibitor of the present invention may be composed of only sea buckthorn seed oil, or may contain other components such as base materials and additives in the technical fields of pharmaceuticals, quasi-drugs, cosmetics, etc., in addition to sea buckthorn seed oil, depending on its form. The content of sea buckthorn seed oil in the gene expression inhibitor of the present invention is not particularly limited as long as it can achieve the effects of the present invention, but is preferably 0.3 v / v% or more, 0.35 v / v% or more, 0.4 v / v% or more, or 0.45 v / v% or more. There is no particular limit to the upper limit of the content of sea buckthorn seed oil in the gene expression inhibitor of the present invention, and it can be 90 v / v% or less, 50 v / v% or less, 10 v / v% or less, 5 v / v% or less, etc., depending on the form. EXAMPLES
[0019] The present invention will be described in more detail below with reference to examples. However, the present invention is not limited to the following examples unless the gist of the present invention is changed.
[0020] 1. Test sample (Sea Buckthorn Seed Oil) Seeds were selected from the residue (including seeds and parts of the skin) after processing sea buckthorn juice using the fruits of H. rhamnoides (produced in Inner Mongolia) and washed with drinking water. The dried material was then crushed and the oil was dissolved and separated by supercritical carbon dioxide extraction (pressure 24-26 MPa, temperature 31.25°C, time 3.5 hours), obtaining a brown, transparent extract. The filling was packaged and sealed under aseptic conditions.
[0021] 2. Test Method (1) Evaluation sample Sea Buckthorn Seed Oil Final concentration: 0.2v / v%, 0.4v / v%, 0.5v / v% ·control Ethanol, final concentration: 0.5 v / v%
[0022] (2) Experimental method ·Cell culture HaCaT cells were cultured in a 10 cm petri dish containing Dulbecco's modified Eagle medium (high glucose) containing 1 v / v% penicillin-streptomycin and 10 v / v% fetal bovine serum (FBS). 2 Incubator (37°C, 5% CO 2 HaCaT cells were cultured until confluent, washed with phosphate-buffered saline (PBS), resuspended in medium, and plated at 1 × 10 5 100 cells / well and incubated with CO 2 The cells were cultured in an incubator.
[0023] Adding samples to cultured cells 24 hours after seeding of HaCaT cells, 1 mL of serum-free Dulbecco's modified Eagle medium (high glucose) containing the sample was added to each well and incubated with CO. 2 Incubator (37°C, 5% CO 2 After 24 hours of culture, LPS (100 μg / mL) treatment was performed.
[0024] Comparison of expression levels of COX2 and 5-LOX genes by real-time PCR HaCaT cells were harvested 24 hours after LPS treatment, and total RNA was extracted using the PureLink RNA Mini kit (Invitrogen). cDNA was synthesized from the extracted total RNA using ReverTra Ace qPCR RT Master Mix with gDNA Remover (TOYOBO). Real-time PCR was performed using the synthesized cDNA as a template on an AriaMX real-time PCR device (Agilent Technologies). THUNDERBIRD SYBR qPCR Mix (TOYOBO) was used for the real-time PCR reaction. As primers for the COX2 gene, a forward primer represented by SEQ ID NO: 1 (5'-AAGTTGGCAGCAAATTGAGCA-3') and a reverse primer represented by SEQ ID NO: 2 (5'-TCCTTTTCTCCTGTGAAGGCG-3') were used. As primers for the 5-LOX gene, a forward primer represented by SEQ ID NO: 3 (5'-TGGCGCGGTGGATTCATAC-3') and a reverse primer represented by SEQ ID NO: 4 (5'-CCAGTCGTCATTCAGCCAGT-3') were used. As primers for the internal standard β-actin, a forward primer represented by SEQ ID NO: 5 (5'-GGGTCAGAAGGACTCCTATG-3') and a reverse primer represented by SEQ ID NO: 6 (5'-GTAACAATGCCATGTTCAAT-3') were used. As real-time PCR reaction conditions, 40 cycles of two-step PCR reaction were performed, which consisted of initial denaturation at 95°C for 3 minutes, denaturation at 95°C for 3 seconds, and annealing / extension at 60°C for 30 seconds.
[0025] 3. Evaluation results Figure 1 shows the results of the expression evaluation test of the 5-LOX gene and the COX2 gene. Figure 1 shows the relative values when the control was set to 1 (n=3, mean ± SD, ** indicates p<0.01), and from the left, the evaluation results are for COX2 and 5-LOX at each concentration of the control and sea buckthorn seed oil. It was confirmed that the expression of the 5-LOX gene was significantly suppressed by the addition of 0.4 v / v% and 0.5 v / v% sea buckthorn seed oil. Similarly, it was confirmed that the expression of the COX2 gene was also significantly suppressed.
Claims
1. A gene expression inhibitor that suppresses the expression of the 5-LOX gene, comprising sea buckthorn seed oil as an active ingredient.
2. The gene expression inhibitor according to claim 1 , which inhibits the expression of the COX2 gene.
3. A gene expression inhibitor that contains sea buckthorn seed oil as an active ingredient and suppresses the expression of the COX2 gene.
4. The gene expression inhibitor according to any one of claims 1 to 3, wherein the seabuckthorn seed oil is a supercritical carbon dioxide extract and / or a subcritical carbon dioxide extract of seabuckthorn seeds.
Citation Information
Patent Citations
Use of cold-pressed edible seed oils, flours, and / or blends thereof as Anti-inflammatory and cox-2 inhibitory agents
US20070281044A1
Cyclooxygenase-2 expression inhibitors
WO2001030341A1
